Regeneron rises after announcing positive trial data on weight-loss drug

Regeneron Pharmaceuticals

09/03/2026 19:40

** Shares of Regeneron REGN.O rises ~2% to $774.29 after the company announced positive trial results of a potential weight-loss drug

** REGN is on track to snap two straight session of losses

** Co said phase 3 trial of olatorepatide conducted by Shanghai-based Hansoh Pharmaceutical in Chinese patients showed positive topline data for the treatment of adults with obesity or who are overweight

** Hansoh holds the development and commercialization rights for olatorepatide in Greater China, while Regeneron holds the rights elsewhere

** The phase 3 trial enrolled 604 adults across 33 clinical sites in mainland China and evaluated once-weekly olatorepatide compared to placebo for 48 weeks, the statement said

** REGN is up 0.9% YTD vs S&P 500 healthcare index's .SPXHC 0.95% decrease

 (Reporting by Chibuike Oguh in New York)

 ((Email: Chibuike.Oguh@thomsonreuters.com; Phone: +332-219-1834; Reuters Messaging: chibuike.oguh.thomsonreuters.com@reuters.net))